Cosmo's stock rises on male pattern hair loss data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 3 December, 2025

If reaching biopharma’s most influential decision-makers is a 2026 priority, this live Q&A will show you where Endpoints is headed — and how brands are turning that reach into impact. Join founder and CEO Arsalan Arif for an insider session built for marketing and communications professionals. Register now.

presented by Writ­ing the Next Chap­ter in CLL Care: Bridg­ing Gaps Through In­no­va­tion and In­sights

spotlight In Focus As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myers

news Bristol Myers pushes back Cobenfy readout after trial site 'irregularities' Pharvaris’ hereditary angioedema drug gets Phase 3 win Cosmo Pharmaceuticals’ shares rise after Phase 3 win in male pattern hair loss

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

ENDPOINTS PHARMA Top drug regulator Rick Pazdur set to leave FDA, prompting industry concern Pentagon reportedly seeks to add WuXi AppTec to military list, bringing fresh uncertainty Hospitals challenge 340B rebate pilot program in Maine federal court New York judge revives Bristol Myers dispute over Celgene deal FDA to remove some monkey testing from monoclonal antibody development

in case you missed it 1. Exclusive: ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisition 2. Helicore stops work on clinical GIP antagonist after Phase 1 results, will focus on other drugs in pipeline 3. News Briefing Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drug